Kw. Vanbesien et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR REFRACTORY AND RECURRENT LOW-GRADE LYMPHOMA - THE CASE FOR AGGRESSIVE MANAGEMENT, Journal of clinical oncology, 13(5), 1995, pp. 1096-1102
Purpose: To evaluate the role of allogeneic bone marrow transplantatio
n (BMT) in recurrent low-grade lymphoma. Patients and Methods: Between
1989 and 1994, 10 patients with chemotherapy-refractory and recurrent
low-grade lymphoma were treated with myeloablative therapy and alloge
neic BMT. All patients had poor prognostic features and had been exten
sively pretreated. Results: Eight patients achieved a complete remissi
on and none have relapsed at a median follow-up time of 816 days (rang
e, 346 to 1,865). Two patients died of early complications. The actuar
ial survival and failure-free survival rates are both 80% +/- 12.6%. F
or surviving patients, the duration of the current remission exceeds t
hat of any previous remission achieved. Conclusion: These results comp
are favorably with those for autologous BMT. allogeneic BMT offers con
siderable promise for the treatment of patients with poor-prognosis lo
w-grade lymphoma. Its role should be further defined in prospective st
udies.